NASDAQ:ALXN
Delisted
Alexion Pharmaceuticals Stock News
$182.50
+0 (+0%)
At Close: May 27, 2022
Will Alexion (ALXN) Beat Estimates Again in Its Next Earnings Report?
12:47pm, Thursday, 21'st Jan 2021
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, NK; Shareholders Are Encouraged to Contact the Firm
04:43pm, Thursday, 14'th Jan 2021
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concern
Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris
11:17am, Thursday, 14'th Jan 2021
Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.
4 Promising Price-to-Book Value Stocks to Buy Now
07:32am, Thursday, 14'th Jan 2021
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
Alexion Pharma pauses further enrollment in COVID-19 drug study
05:13pm, Wednesday, 13'th Jan 2021
Alexion Pharmaceuticals Inc. ALXN said late Wednesday it stopped enrolling patients in a clinical study testing a treatment for severe COVID-19 patients based on the recommendation of a data monitorin
ALXN or BMRN: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 07'th Jan 2021
ALXN vs. BMRN: Which Stock Is the Better Value Option?
ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders Are Encouraged to Contact the Firm
11:26am, Tuesday, 05'th Jan 2021
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerni
With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition Targets
12:38pm, Thursday, 24'th Dec 2020
Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was ann
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers - ALXN, TCF, CATM, TCP
10:59am, Thursday, 24'th Dec 2020
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concern
Should Investors Consider This Biotech Takeover Target?
11:55am, Monday, 21'st Dec 2020
Getting in on the extensive merger and acquisition game of large pharmaceutical companies is the ultimate endgame for Exelixis, a biotech that already boasts an established cancer-focused product line
5 Biotech Stocks That More Than Doubled This Year
09:47am, Monday, 21'st Dec 2020
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
3 Biotech Stocks That Could Explode Higher in 2021
08:43am, Monday, 21'st Dec 2020
Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.
3 Great Stocks You Can Buy on Sale
07:44am, Sunday, 20'th Dec 2020
These stocks have been struggling of late. Now could be a great time to scoop them up.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Alexion Pharmaceuticals, Inc. - ALXN
09:00pm, Friday, 18'th Dec 2020
NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York C
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - ALXN, CATM, TCP, PRVL
01:01pm, Wednesday, 16'th Dec 2020
NEW YORK, Dec. 16, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concern